Thursday, November 12, 2026

US Federal Reserve Delays Rate Cuts to Late 2026 as Oil Inflation Spreads Globally

Federal Reserve officials now expect interest rates to remain elevated until late 2026, citing persistent oil-driven inflation that affects economies worldwide. The shift marks a hawkish turn from earlier projections and signals prolonged higher borrowing costs across global credit markets. Treasury yields jumped 10 basis points as investors worldwide repriced portfolios for an extended high-rate environment.

US Federal Reserve Delays Rate Cuts to Late 2026 as Oil Inflation Spreads Globally
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Federal Reserve officials expect interest rates to stay elevated until late 2026, a timeline that extends the global high-rate regime affecting borrowing costs from Wall Street to Frankfurt and Tokyo.

Atlanta Fed President Raphael Bostic stated he sees "little suggesting price pressures will dissipate before mid to late 2026." Minneapolis Fed President Neel Kashkari said he is "no longer confident" in earlier rate cut projections. The hawkish shift reflects oil price volatility driven by Middle East geopolitical tensions that ripple through economies worldwide.

San Francisco Fed President Mary Daly acknowledged that "oil price shock is a real thing depending on duration," while New York Fed President John Williams warned geopolitical conflicts "could affect the near-term inflation outlook." Oil prices affect consumer inflation globally, with European and Asian central banks facing similar pressures despite different monetary policy cycles.

The 10-year US Treasury yield jumped 10 basis points in under one week, influencing government bond markets from Germany to Australia. Global investors are repricing portfolios for higher-for-longer rates through 2027, affecting capital flows to emerging markets and sovereign debt valuations.

Corporate borrowing costs will remain elevated worldwide. Business development companies and private equity firms in the US face NAV volatility and reduced deal volume, dynamics mirrored in London and Hong Kong markets. Credit spreads in BB and B rated instruments may widen as investors demand additional compensation for illiquidity.

Banking institutions across advanced economies will maintain tight lending standards. Commercial real estate markets from New York to Singapore face headwinds as acquisition financing costs stay prohibitive. Leveraged buyout activity is expected to decline as financing remains restrictive.

Fed fund futures pricing for December 2026 and June 2027 will indicate whether global markets fully incorporate this timeline. EBITDA coverage ratios at leveraged companies provide early warning signals of credit stress that could spread across interconnected international financial systems.


Sources:
1 Yahoo Finance, "War escalation, jobs report fallout, and Oracle earnings: What to watch this week" (March 08, 2026)
2 Yahoo Finance, "Traders revamp Fed interest-rate cut bets as jobs dip, oil rises in Iran war" (March 07, 2026)
3 Yahoo Finance, "AI disruption looms over markets with US jobs data on tap" (March 02, 2026)
4 Yahoo Finance, "Fed's Treasury bill buying on track to moderate, amid work to rejigger bond holdings" (March 18, 2026)
5 Yahoo Finance, "‘If they rise, they rise’: Trump has zero concern for spiking US gas prices — says Iran operation ‘" (March 08, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com